Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
21 févr. 2019 16h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019, the Compensation Committee...
Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference
24 janv. 2019 11h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church, Celsion’s Executive Vice...
Celsion Announces Publication of ThermoDox® Study Results in Radiology
17 janv. 2019 08h30 HE
|
Celsion CORP
Publication Highlights Phase I Data Supporting Safety and Feasibility of Treatment with ThermoDox® and Non-Invasive, Focused Ultrasound University of Oxford’s Findings Provide Additional...